The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein]
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]
[3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in decreased expression of BCL2 protein; [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased expression of BCL2 protein; [Mycophenolic Acid co-treated with Hypoxanthine] results in decreased expression of BCL2 protein
[3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in increased activity of CASP3 protein; [Mycophenolic Acid co-treated with Hypoxanthine] results in increased activity of CASP3 protein
[Thymidine co-treated with Hypoxanthine co-treated with 5,6,7,8-tetrahydrofolic acid] inhibits the reaction [Methotrexate results in decreased expression of MTR protein]; [Thymidine co-treated with Hypoxanthine] inhibits the reaction [Methotrexate results in decreased expression of MTR protein]
[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein]
[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased expression of SLC22A12 protein]
[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA; [Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA]; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 mRNA]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC22A6 protein]
[[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical; [XDH protein co-treated with Hypoxanthine] results in increased secretion of CXCL8 protein [Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein; Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein]; Polysaccharides inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in increased activity of XDH protein] [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]
browse the term
